Altered cerebrospinal fluid neurofilament light chain but not neurogranin levels are associated with response to ocrelizumab treatment in relapsing remitting multiple sclerosis: a preliminary study.
Tuğçe KızılayEce AkbayirRuziye ErolAyça Simay DemirDuygu Özkan YaşargünVuslat YilmazErdem TuzunRecai TurkogluPublished in: European neurology (2024)
Our results confirm that NFL effectively monitors treatment response of RRMS patients under ocrelizumab treatment. Neurogranin does not appear to exhibit a similar benefit in screening of RRMS disease activity. Nevertheless, lower neurogranin levels are associated with increased disability in RRMS indicating a potential disease activity biomarker function.
Keyphrases
- disease activity
- multiple sclerosis
- systemic lupus erythematosus
- rheumatoid arthritis
- rheumatoid arthritis patients
- ankylosing spondylitis
- cerebrospinal fluid
- juvenile idiopathic arthritis
- end stage renal disease
- ejection fraction
- chronic kidney disease
- prognostic factors
- newly diagnosed
- white matter
- climate change